KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

被引:1875
作者
Eckardt, Kai-Uwe
Kasiske, Bertram L.
机构
关键词
Guideline; KDIGO; kidney transplant recipient care; immunosuppression; graft monitoring; infectious diseases; cardiovascular disease; malignancy; mineral and bone disorder; hematological complications; hyperuricemia; gout; growth; sexual function; fertility; mental health; HEPATITIS-B-VIRUS; RENAL-ALLOGRAFT RECIPIENTS; POSTTRANSPLANT DIABETES-MELLITUS; QUALITY-OF-LIFE; HEMOLYTIC-UREMIC SYNDROME; I MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; RANDOMIZED CONTROLLED-TRIAL; DELAYED GRAFT FUNCTION; HUMAN GROWTH-HORMONE; EPSTEIN-BARR-VIRUS;
D O I
10.1111/j.1600-6143.2009.02834.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the monitoring, management, and treatment of kidney transplant recipients is intended to assist the practitioner caring for adults and children after kidney transplantation. The guideline development process followed an evidence-based approach, and management recommendations are based on systematic reviews of relevant treatment trials. Critical appraisal of the quality of the evidence and the strength of recommendations followed the Grades of Recommendation Assessment, Development, and Evaluation (GRADE) approach. The guideline makes recommendations for immunosuppression, graft monitoring, as well as prevention and treatment of infection, cardiovascular disease, malignancy, and other complications that are common in kidney transplant recipients, including hematological and bone disorders. Limitations of the evidence, especially on the lack of definitive clinical outcome trials, are discussed and suggestions are provided for future research.
引用
收藏
页码:S1 / S155
页数:155
相关论文
共 931 条
[1]   Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up [J].
Aakhus, S ;
Dahl, K ;
Wideroe, TE .
CLINICAL TRANSPLANTATION, 2004, 18 (05) :596-604
[2]   Cardiovascular morbidity and risk factors in renal transplant patients [J].
Aakhus, S ;
Dahl, K ;
Wideroe, TE .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (03) :648-654
[3]   The influence of obesity on short- and long-term graft and patient survival after renal transplantation [J].
Aalten, Jeroen ;
Christiaans, Maarten H. ;
de Fijter, Hans ;
Hene, Ronald ;
van der Heijde, Jaap Homan ;
Roodnat, Joke ;
Surachno, Janto ;
Hoitsma, Andries .
TRANSPLANT INTERNATIONAL, 2006, 19 (11) :901-907
[4]   New-onset gout after kidney transplantation: Incidence, risk factors and implications [J].
Abbott, KC ;
Kimmel, PL ;
Dharnidharka, V ;
Oglesby, RJ ;
Agodoa, LY ;
Caillard, S .
TRANSPLANTATION, 2005, 80 (10) :1383-1391
[5]   Differing manifestations of hepatitis C and tacrolimus on hospitalized diabetes mellitus occurring after kidney transplantation [J].
Abbott, KC ;
Bernet, VJ ;
Agodoa, LY ;
Yuan, CM .
ANNALS OF EPIDEMIOLOGY, 2005, 15 (08) :558-563
[6]   Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus [J].
Abbott, KC ;
Lentine, KL ;
Bucci, JR ;
Agodoa, LY ;
Koff, JM ;
Holtzmuller, KC ;
Schnitzler, MA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12) :3166-3174
[7]   Hospitalized psychoses after renal transplantation in the United States: Incidence, risk factors, and prognosis [J].
Abbott, KC ;
Agodoa, LY ;
O'Malley, PG .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (06) :1628-1635
[8]   Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients [J].
Abraham, MA ;
Thomas, PP ;
John, GT ;
Job, V ;
Shankar, V ;
Jacob, CK .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (01) :215-216
[9]   Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs Diabetes Trial [J].
Abraira, C ;
Duckworth, W ;
McCarren, M ;
Emanuele, N ;
Arca, D ;
Reda, D ;
Henderson, W .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) :314-322
[10]   Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft [J].
Adams, PL ;
Iskandar, SS ;
Rohr, MS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (03) :552-554